Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
HKD 16.26
(-0.49%)
HKD 16.26
(-0.49%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.98 Billion CNY | 57.45% |
| 2022 | -4.67 Billion CNY | -62.54% |
| 2021 | -2.87 Billion CNY | -13.5% |
| 2020 | -2.53 Billion CNY | -621.87% |
| 2019 | -351.06 Million CNY | 83.99% |
| 2018 | -2.19 Billion CNY | -723.58% |
| 2017 | -266.29 Million CNY | -139.07% |
| 2016 | -111.38 Million CNY | 69.39% |
| 2015 | -363.92 Million CNY | -1121.56% |
| 2014 | -29.79 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.64 Billion CNY | 17.2% |
| 2024 Q2 | -142.03 Million CNY | 91.38% |
| 2023 Q3 | -2.65 Billion CNY | 22.98% |
| 2023 Q4 | -1.98 Billion CNY | 25.06% |
| 2023 FY | -1.98 Billion CNY | 57.45% |
| 2023 Q1 | -3.62 Billion CNY | 22.49% |
| 2023 Q2 | -3.44 Billion CNY | 4.89% |
| 2022 FY | -4.67 Billion CNY | -62.54% |
| 2022 Q4 | -4.67 Billion CNY | -188.28% |
| 2022 Q3 | -1.62 Billion CNY | 29.45% |
| 2022 Q2 | -2.29 Billion CNY | 36.66% |
| 2022 Q1 | -3.62 Billion CNY | -26.18% |
| 2021 Q3 | -2.52 Billion CNY | 26.05% |
| 2021 Q4 | -2.87 Billion CNY | -13.83% |
| 2021 Q1 | -2.4 Billion CNY | 5.07% |
| 2021 FY | -2.87 Billion CNY | -13.5% |
| 2021 Q2 | -3.41 Billion CNY | -42.03% |
| 2020 Q1 | 1.22 Billion CNY | 447.77% |
| 2020 FY | -2.53 Billion CNY | -621.87% |
| 2020 Q2 | 459.56 Million CNY | -62.36% |
| 2020 Q3 | -3.24 Billion CNY | -805.36% |
| 2020 Q4 | -2.53 Billion CNY | 21.82% |
| 2019 Q1 | -1.72 Billion CNY | 21.53% |
| 2019 FY | -351.06 Million CNY | 83.99% |
| 2019 Q4 | -351.06 Million CNY | 0.0% |
| 2019 Q2 | -1.47 Billion CNY | 14.3% |
| 2018 Q3 | 28.46 Million CNY | 117.54% |
| 2018 FY | -2.19 Billion CNY | -723.58% |
| 2018 Q4 | -2.19 Billion CNY | -7806.17% |
| 2018 Q2 | -162.23 Million CNY | -139.21% |
| 2018 Q1 | 413.73 Million CNY | 255.36% |
| 2017 FY | -266.29 Million CNY | -139.07% |
| 2017 Q1 | -231.09 Million CNY | -107.47% |
| 2017 Q2 | -231.09 Million CNY | 0.0% |
| 2017 Q4 | -266.29 Million CNY | 0.0% |
| 2016 FY | -111.38 Million CNY | 69.39% |
| 2016 Q1 | -180.07 Million CNY | 50.52% |
| 2016 Q2 | -180.07 Million CNY | 0.0% |
| 2016 Q3 | -111.38 Million CNY | 38.14% |
| 2016 Q4 | -111.38 Million CNY | 0.0% |
| 2015 Q2 | -10.48 Million CNY | 0.0% |
| 2015 Q1 | -10.48 Million CNY | 64.82% |
| 2015 Q4 | -363.92 Million CNY | 0.0% |
| 2015 Q3 | -363.92 Million CNY | -3372.55% |
| 2015 FY | -363.92 Million CNY | -1121.56% |
| 2014 FY | -29.79 Million CNY | 0.0% |
| 2014 Q4 | -29.79 Million CNY | 0.0% |
| 2014 Q3 | -29.79 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -2505.213% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 137.776% |